Persons experiencing homelessness Other
Conditions
Interventions
In addition to usual care, the PHOENIx team (pharmacist independent prescriber in partnership with a third sector charity worker) will assess the participants’ physical, mental and addictions health,
Sponsors
University of Birmingham
Eligibility
Sex/Gender
All
Age
18 Years to 120 Years
Inclusion criteria
Inclusion criteria: 1. Aged 18 years old and over 2. Experiencing homelessness including: 2.1. Rooflessness 2.2. Houselessness 2.3. Insecure or inadequate housing as per the ETHOS typology 2.4. Staying in homeless shelters 2.5. Rough sleeping 2.6. Staying in temporary accommodation, such as bed and breakfasts (B&Bs), hostels, squats; or that sofa surfing between family and friends’ houses 3. Attending or service users of one of the designated community pharmacies
Exclusion criteria
Exclusion criteria: 1. Living in accommodation with 24-hour support which includes in-house medical care 2. Intoxicated or (in the opinion of the researcher) posing a safety risk to staff and lacking the capacity to consent
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 1. The randomisation process and recruitment rate measured by the numbers invited to participate, numbers recruited at baseline 2. Retention of those remaining in the trial at 3 months and 6 months follow up 3. Adherence to the intervention measured by the proportion of participants attending the intervention at planned visits 4. Proportion of participants with patient-reported outcomes completed measured by the number of participants who complete the questionnaire booklet at planned visits 5. Proportion of participants with routinely collected Emergency Department visits and mortality data available at 6 months | — |
Secondary
| Measure | Time frame |
|---|---|
| Clinical measures: 1. Number and cause of Emergency Department visits measured by patient-reported and routinely collected data at 3 and 6 months 2. Number and cause of primary care general practice visits measured by patient-reported and routinely collected data at 3 and 6 months 3. Mortality measured by routinely collected data at 6 months 4. Medication changes (prescribed) and taken (in the case of opioid substitution therapy where supervised) measured through patient-reported and routinely collected data at 3 and 6 months 5. Number and cause of hospitalisation measured by patient-reported and routinely collected data at 3 and 6 months 6. Intervention acceptability measured by qualitative interviews with patients, the intervention delivery team and stakeholders as an ongoing process evaluation 7. Generic health-related quality of life score and health thermometer score measured by EQ-5D-5L at 3 months and 6 months 8. Frailty measured by Fried’s adapted frailty phenotype at 3 months and 6 months 9. Respiratory health measured by Peak Expiratory Flow Rate, MRC Dyspnoea scale and COPD Assessment Test (CAT) at 3 months and 6 months 10. Blood pressure measured by blood pressure monitors at 3 months and 6 months Addiction measures: 1. Number of participants experiencing drug overdoses not requiring an Emergency Department visit and the number of overdoses measured by patient-reported data at 3 months and 6 months 2. Number of participants (and number of times) referred to drug and alcohol services, rehab, mental health and GP, and the numbers attending subsequently measured by patient-reported and routinely collected data at 3 and 6 months 3. Numbers and time to commencement on opiate substitute treatment (OST)/benzodiazepine/heroin-assisted treatment and collecting = 80% of daily doses measured by routinely collected data at 3 months and 6 months 4. Number of participants treated with and time to minimum therapeutic OST dose measured by routinely collected data at | — |
Countries
England, Scotland, United Kingdom
Contacts
Public ContactSarah Tearne
Outcome results
None listed